The Pattern of Mobile Phone Use and Prevalence of Self-Reported Symptoms in Elementary and Junior High School Students in Shiraz, Iran

por Mortazavi, Seyed Mohammad Javad, Atefi, Mohammad, Kholghi, Fatemeh
Publicado 2011

Scientific Publications on Medical Ethics in Thomson Reuters Database, 1990-2010

por Morovati, Marzieh, Ejraei, Akbar, Hadi, Zohre, Atefi, Mohammad, Morovati, Mohammad Javad
Publicado 2012

Lactate, a Neglected Factor for Diabetes and Cancer Interaction

por Wu, Yong, Dong, Yunzhou, Atefi, Mohammad, Liu, Yanjun, Elshimali, Yahya, Vadgama, Jaydutt V.
Publicado 2016

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

por Lassen, Amanda, Atefi, Mohammad, Robert, Lidia, Wong, Deborah JL, Cerniglia, Michael, Comin-Anduix, Begonya, Ribas, Antoni
Publicado 2014

Proinflammatory Cytokines IL-6 and TNF-α Increased Telomerase Activity through NF-κB/STAT1/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells

por Chung, Seyung S., Wu, Yong, Okobi, Quincy, Adekoya, Debbie, Atefi, Mohammad, Clarke, Orette, Dutta, Pranabananda, Vadgama, Jaydutt V.
Publicado 2017

CRAF R391W is a melanoma driver oncogene

por Atefi, Mohammad, Titz, Bjoern, Tsoi, Jennifer, Avramis, Earl, Le, Allison, Ng, Charles, Lomova, Anastasia, Lassen, Amanda, Friedman, Michael, Chmielowski, Bartosz, Ribas, Antoni, Graeber, Thomas G.
Publicado 2016

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

por Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J
Publicado 2009

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

por Atefi, Mohammad, Titz, Bjoern, Avramis, Earl, Ng, Charles, Wong, Deborah JL, Lassen, Amanda, Cerniglia, Michael, Escuin-Ordinas, Helena, Foulad, David, Comin-Anduix, Begonya, Graeber, Thomas G, Ribas, Antoni
Publicado 2015

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

por Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Publicado 2011

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

por Escuin-Ordinas, Helena, Elliott, Mark W, Atefi, Mohammad, Lee, Michelle, Ng, Charles, Wei, Liu, Comin-Anduix, Begoña, Montecino-Rodriguez, Encarnacion, Avramis, Earl, Radu, Caius, Sharp, Leslie L, Ribas, Antoni
Publicado 2013

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

por Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Publicado 2014

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

por Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni
Publicado 2015

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma

por Titz, Bjoern, Lomova, Anastasia, Le, Allison, Hugo, Willy, Kong, Xiangju, ten Hoeve, Johanna, Friedman, Michael, Shi, Hubing, Moriceau, Gatien, Song, Chunying, Hong, Aayoung, Atefi, Mohammad, Li, Richard, Komisopoulou, Evangelia, Ribas, Antoni, Lo, Roger S, Graeber, Thomas G
Publicado 2016

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

por von Euw, Erika, Atefi, Mohammad, Attar, Narsis, Chu, Connie, Zachariah, Sybil, Burgess, Barry L, Mok, Stephen, Ng, Charles, Wong, Deborah JL, Chmielowski, Bartosz, Lichter, David I, Koya, Richard C, McCannel, Tara A, Izmailova, Elena, Ribas, Antoni
Publicado 2012

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

por Poulikakos, Poulikos I., Persaud, Yogindra, Janakiraman, Manickam, Kong, Xiangju, Ng, Charles, Moriceau, Gatien, Shi, Hubing, Atefi, Mohammad, Titz, Bjoern, Gabay, May Tal, Salton, Maayan, Dahlman, Kimberly B., Tadi, Madhavi, Wargo, Jennifer A., Flaherty, Keith T., Kelley, Mark C., Misteli, Tom, Chapman, Paul B., Sosman, Jeffrey A., Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Rosen, Neal, Solit, David B.
Publicado 2011

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors

por Escuin-Ordinas, Helena, Li, Shuoran, Xie, Michael W., Sun, Lu, Hugo, Willy, Huang, Rong Rong, Jiao, Jing, de-Faria, Felipe Meira, Realegeno, Susan, Krystofinski, Paige, Azhdam, Ariel, Komenan, Sara Marie D., Atefi, Mohammad, Comin-Anduix, Begoña, Pellegrini, Matteo, Cochran, Alistair J., Modlin, Robert L., Herschman, Harvey R., Lo, Roger S., McBride, William H., Segura, Tatiana, Ribas, Antoni
Publicado 2016